Qureshi Sajid S, Bhagat Monica, Kembhavi Seema, Vora Tushar, Ramadwar Mukta, Talole Sanjay
Division of Pediatric Surgical Oncology, Department of Surgical Oncology, Tata Memorial Centre, Ernest Borges Road, Parel, 400012, Bombay, India,
Pediatr Surg Int. 2015 Jun;31(6):573-9. doi: 10.1007/s00383-015-3713-0. Epub 2015 Apr 23.
To determine the outcomes of resection of satellite lesions in PRE-treatment Tumor EXTension (PRETEXT) II and III multifocal hepatoblastoma irrespective of their disappearance after chemotherapy. To compare the overall outcomes of multifocal and unifocal hepatoblastoma.
Fourteen patients with PRETEXT II (n = 7) and III (n = 7) multifocal hepatoblastoma treated between April 2006 and July 2014 were analyzed and their outcomes were compared with PRETEXT II and III unifocal hepatoblastoma treated in the similar period.
Satellite lesion or the affected segments with disappeared satellite lesions were resected in 11 patients. Amongst them, all relapses were distant except one in the liver. In contrast, two of three patients developed liver relapse when the affected segments were not resected. None of the patients receiving intensive chemotherapy based on SIOPEL-3 guidelines developed a relapse. The 3-year event-free and overall survival were 38.6 and 42.9% in multifocal hepatoblastoma and 86.4 and 92.4% in unifocal hepatoblastoma (p = 0.001). Multifocality (p = 0.002) and AFP >10,000 after induction chemotherapy significantly affected event-free survival (p = 0.01).
Multifocal hepatoblastoma is associated with poor outcomes as compared to unifocal hepatoblastoma. These preliminary observations of relapse and the role of chemotherapy intensification deserve further study in a multicenter controlled trial setting.
确定预处理肿瘤扩展(PRETEXT)II期和III期多灶性肝母细胞瘤卫星灶切除的结果,无论其在化疗后是否消失。比较多灶性和单灶性肝母细胞瘤的总体结果。
分析2006年4月至2014年7月期间治疗的14例PRETEXT II期(n = 7)和III期(n = 7)多灶性肝母细胞瘤患者,并将其结果与同期治疗的PRETEXT II期和III期单灶性肝母细胞瘤进行比较。
11例患者切除了卫星灶或卫星灶消失的受累节段。其中,除1例肝内复发外,所有复发均为远处复发。相比之下,3例未切除受累节段的患者中有2例发生肝复发。根据SIOPEL-3指南接受强化化疗的患者均未复发。多灶性肝母细胞瘤的3年无事件生存率和总生存率分别为38.6%和42.9%,单灶性肝母细胞瘤为86.4%和92.4%(p = 0.001)。多灶性(p = 0.002)和诱导化疗后甲胎蛋白>10,000显著影响无事件生存率(p = 0.01)。
与单灶性肝母细胞瘤相比,多灶性肝母细胞瘤的预后较差。这些关于复发的初步观察结果以及强化化疗的作用值得在多中心对照试验中进一步研究。